NKTX vs. AVIR, SBTX, ATAI, PGEN, VTYX, VRCA, KMDA, ORGO, CRMD, and NLTX
Should you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Atea Pharmaceuticals (AVIR), Silverback Therapeutics (SBTX), Atai Life Sciences (ATAI), Precigen (PGEN), Ventyx Biosciences (VTYX), Verrica Pharmaceuticals (VRCA), Kamada (KMDA), Organogenesis (ORGO), CorMedix (CRMD), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical preparations" industry.
Atea Pharmaceuticals (NASDAQ:AVIR) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, institutional ownership, media sentiment, valuation and risk.
Nkarta has a consensus target price of $17.83, indicating a potential upside of 178.65%. Given Atea Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Atea Pharmaceuticals.
Nkarta has lower revenue, but higher earnings than Atea Pharmaceuticals. Nkarta is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Atea Pharmaceuticals had 1 more articles in the media than Nkarta. MarketBeat recorded 2 mentions for Atea Pharmaceuticals and 1 mentions for Nkarta. Atea Pharmaceuticals' average media sentiment score of 1.00 beat Nkarta's score of 0.38 indicating that Nkarta is being referred to more favorably in the news media.
Atea Pharmaceuticals has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.
86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 14.5% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 5.6% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Nkarta received 28 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 71.43% of users gave Nkarta an outperform vote while only 47.22% of users gave Atea Pharmaceuticals an outperform vote.
Nkarta's return on equity of -23.07% beat Atea Pharmaceuticals' return on equity.
Summary
Atea Pharmaceuticals and Nkarta tied by winning 8 of the 16 factors compared between the two stocks.
Get Nkarta News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
